Nintedanib for treating idiopathic pulmonary fibrosis when forced vital capacity is above 80% predicted

  • Technology appraisal guidance
  • TA864
  • Published: 

History

Documents created during the development process.

Expected publication

Final draft guidance

Invitation to participate

Draft scope documents